English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Breast cancer (BC) is a common malignant tumor in women, accounting for most malignant tumors in women. Approximately 1.2 million new BC patients are diagnosed and around 500,000 people die of BC each year worldwide (1,2). Clinical studies have shown that the incidence of bone metastases (BMs) in BC is highest in two common tumor metastatic organs, the lung and liver (3,4). Since the BM mechanism of BC has not been fully elucidated, BM cannot be cured, resulting in a high mortality rate (5,6). Denosumab targets the inhibition of receptor activator of NF-κB ligand (RANKL), which inhibits the activation of osteoclasts and decreases bone absorption and destruction (7). It has been widely used to treat or prevent BM of solid tumors, such as BC, kidney cancer and urinary Original Article

Denosumab inhibits MCF-7 cell line-induced spontaneous osteoclastogenesis via the RANKL/MALAT1/miR-124 axis